PFIZER INC reported first-quarter adjusted profit of $0.75 per share on Tuesday morning, beating analyst estimates of $0.72 per share. Total revenue reached $14.45 billion, exceeding the $13.79 billion projected by LSEG data. Strong performance in legacy drugs is offsetting sharp declines in COVID-related product sales as the drugmaker navigates patent cliffs.

Legacy Portfolio Offsets COVID Decline